undamentalytics Newsletter
Sign in

Abbott Laboratories key statistics and ratios

In fiscal 2025, Abbott Laboratories had return on equity of 13.1%, an operating margin of 18.2%, debt equal to 24.8% of equity and a current ratio of 1.58. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin———————56.4%54.7%58.4%58.5%56.6%57.0%56.1%55.2%55.4%56.4%56.6%
Operating margin20.3%17.3%7.6%7.1%10.9%12.8%14.1%14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%15.8%
Net margin18.7%13.2%22.1%31.3%13.1%11.3%21.7%6.7%1.7%7.7%11.6%13.0%16.4%15.9%14.3%31.9%14.7%11.6%
Free-cash-flow margin20.1%22.0%34.9%39.5%11.1%12.8%9.1%10.0%16.2%16.0%14.1%16.5%20.1%17.9%12.6%15.1%16.7%16.8%
Return on equity24.8%20.2%20.1%23.3%9.9%9.8%20.7%6.7%1.9%7.7%12.0%14.1%20.6%19.1%15.2%31.1%13.1%10.5%
Return on assets10.9%8.2%7.8%9.4%4.7%5.4%10.7%3.0%0.7%3.3%5.5%6.4%9.6%9.3%7.8%17.3%7.8%5.5%
Asset turnover0.590.620.350.300.360.480.490.440.420.430.470.490.580.580.540.540.530.48
Current ratio1.791.291.542.362.021.301.544.022.261.621.441.721.851.631.641.671.581.38
Debt to equity71.1%83.4%63.1%76.6%26.1%36.4%42.4%107.1%90.4%64.1%58.3%57.2%50.4%45.7%38.0%29.6%24.8%63.8%
Interest cover (operating income ÷ interest)12.0x11.0x4.5x4.3x14.7x17.3x17.6x7.0x1.7x4.4x6.8x9.8x15.8x15.0x10.2x12.2x16.3x9.6x
Effective tax rate20.1%19.0%8.9%—2.6%31.7%18.1%24.8%84.2%18.8%9.6%10.0%13.9%16.5%14.1%—22.9%27.8%
R&D as % of revenue8.9%10.6%7.1%7.7%7.0%6.6%6.9%6.9%8.3%7.5%7.6%7.0%6.4%6.6%6.8%6.8%6.6%6.8%
SG&A as % of revenue27.3%29.5%34.4%35.4%32.4%32.3%33.3%32.3%33.5%31.9%30.6%28.0%26.3%25.8%27.3%27.9%27.8%29.9%
Capital spending as % of revenue3.5%2.9%7.0%9.4%5.8%5.3%5.4%5.4%4.1%4.6%5.1%6.3%4.4%4.1%5.5%5.3%4.9%4.5%
Free cash flow ÷ net income107.7%166.9%158.2%126.1%84.6%113.7%42.0%148.7%929.8%207.2%122.0%127.3%122.3%112.6%88.4%47.4%113.4%144.2%
Dividends ÷ net income42.0%57.7%62.1%53.4%34.2%58.8%32.6%109.9%387.6%83.4%61.6%57.0%45.3%47.7%62.1%28.6%63.1%78.5%
Dividends and buybacks ÷ free cash flow52.4%45.8%40.3%73.8%114.1%136.1%198.3%99.0%44.3%45.1%66.4%51.8%63.6%91.0%94.5%80.8%67.7%77.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $109.2bn
Short-term assets $24.5bnLonger-term assets $84.7bn
What it owes, and who funded it · $68.9bn
Short-term liabilities $17.8bnShareholders' equity $51.1bn
  • Short-term assets cover short-term liabilities $24.5bn of assets due within a year against $17.8bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $5.1bn of cash against $32.6bn of debt.
  • Debt below 40% of shareholders' equity Debt is 64% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 48% to 64% over five years.
  • A year's operating cash flow covers at least 20% of debt $9.9bn of operating cash flow against $32.6bn of debt.
  • Operating profit covers interest at least five times over Operating income of $7.3bn against $766m of interest.

From Abbott Laboratories's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

72 /100

Strong moat

How hard Abbott Laboratories's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 8 / 20

    Net income has been a median 6.0% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 55.5%, moving by 2.9 percentage points (standard deviation) across 10 years.

  • Durability 11 / 20

    Operating margin has been a median 15.5%; its worst year was 7.8%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 15.1% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 2.5% over five years; stock-based pay has been a median 1.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABT vs MDTABT vs SYKABT vs GEHC

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Abbott Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abbott Laboratories.